Leflunomide in treatment of RA patents preliminary estimation of therapeutical efficiency and side effects
Journal Title: Reumatologia - Year 2006, Vol 44, Issue 1
Abstract
In the preliminary estimation there were studied efficiency and safety of therapy leflunomid in patients with RA. The drug was given p. o. to a group of 158 patients (150 females and 8 males) for 3 days 100 mg/24 h, and then again 20 mg/24 h. The age of patients varied between 19-78 (average age was 55 years), with average duration time of the disease 10 years and 2 months. All of the patients were previously unsuccessfully treated with other DMARDS. All of the patients had high activity of disease estimated by DAS 28 ≥5.1 61.4% of patients were treated with long-term glicocorticosteroids. Time of trial was scheduled for 6 months. The therapeutical effect was initially estimated on the basis of a group of 43 patients who took the medicine for 91-120 days. Good and average therapeutical efficiency of treatment was observed in 76.73% of patients. Efficiency was expressed by lowering DAS 28 by 0.6-1.2 in a group of 11.62% of patients and 1.2 in a group of 65.11% of patients. In a group of 3.79% of patients the treatment was stopped because of complete lack of therapeutical effect. Frequency of side effects was initially estimated in a group of 158 patients. Treatment was interrupted in the group of 8.86% of patients because of such side effects as: diarrheas, elevation of transaminazes, leukopenia and trombocytopenia, skin changes and dizziness. Observations are continued. Preliminary results of observations allow for positive evaluation of treatment with leflunomid in RA patients.
Authors and Affiliations
Maria Rell-Bakalarska, Janusz Jaworski, Lidia Rutkowska-Sak, Małgorzata Wieczorek, Ewa Klimczak, Bożena Kowalczuk, Krzysztof Wojciech Rell
Keywords
Related Articles
- EP ID EP144333
- DOI -
- Views 52
- Downloads 0
Limfocyty B – funkcje fizjologiczne i udział w patogenezie reumatoidalnego zapalenia stawów
Udział limfocytów B w odpowiedzi przeciwinfekcyjnej nie ogranicza się do syntezy przeciwciał swoistych dla patogenu, ponieważ komórki te mają zdolność pełnienia wielu innych funkcji (prezentacji antygenu, wspomagania akt...
SAPHO-a case report
The case of the 36-year old female patient with osteosclerotic and osteolotic osteoarticular changes and hyperostosis of the spine is presented. She had suffered from spinal pain for ten years and she had clavicular pain...
Cross-reacting anti-cardiolipin antibodies as a marker of presence of endotoxin in the sera and synovial fluids of patients with arthritis
Analysing the large groups of sera and synovial fluids from patients with arthritis we observed, that frequency of the aCl presence in above mentioned materials was relatively high (about 30-50%) – very similar to aCl fr...
Celowość oznaczania surowiczych autoprzeciwciał niezaliczanych do kryteriów diagnostycznych układowych chorób tkanki łącznej
W pracy omówiono autoprzeciwciała pomocnicze, tj. niezaliczone do kryteriów diagnostycznych, ale charakteryzujące się stosunkowo wysoką swoistością (choć niekoniecznie wysoką częstością występowania) dla danej jednostki...
The modern diagnostics of Sjögrena
Sjögren's syndrome is considered to be a chronic systemic exocrinopathy of unclear origin, characterized by lymphoid cells infiltration in tissue of exocrine glands resulting in their partial dysfunction or fatal failure...